Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
New Delhi: For the NEET SS 2024 aspirants seeking admission to DM Virology, MD/DNB (Microbiology) has been designated as the feeder qualifications.
DM Virology or Doctorate of Medicine in Virology also known as DM in Virology is a super specialty level course for doctors in India that is done by them after completion of their postgraduate medical degree course. The duration of this super specialty course is 3 years, and it focuses on the study of diagnosis, prevention and management of viral infections.
The NEET SS 2024 correction window ended recently. As per the information bulletin released by the National Board of Examinations (NBE), the feeder qualification for DM Virology is MD/DNB (Microbiology) defined by the NBE and is subject to changes by the NBE.
The eligibility criteria for DM Virology are defined as the set of rules or minimum prerequisites that aspirants must meet in order to be eligible for admission, which include:
|
Name of course |
Course Type |
Prior Eligibility Requirement |
|
Virology |
DM |
MD/DNB (Microbiology) |
NEET SS 2024:
ELIGIBILITY CRITERIA
The applicant must meet/fulfil the following criteria-
1 Candidates who have a recognized postgraduate medical Degree/Provisional Pass Certificate (MD/MS/DNB) or equivalent recognized qualification or are likely to have the same by 30th April 2025 by eligible feeder speciality qualifications for super speciality courses as mentioned in Annexure B of this Information Bulletin can apply for NEET-SS 2024.
2 Candidates found to be ineligible at any stage of NEET-SS 2024 will not be permitted to appear in the examination. In the unlikely event of any ineligible candidate appearing and/or being successful in NEET-SS 2024, the result/ candidature of such candidate shall be cancelled and/or is deemed to be cancelled as and when the ineligibility is detected.
3 The cutoff date for qualifying MD/MS/DNB Broad Specialty/ eligible feeder qualification towards determination of eligibility for appearing in NEET-SS 2024 shall be 30th April 2025.
4 Requests for appearing in NEET-SS 2024 from candidates who are qualifying and/or getting the results of their MD/MS/DNB qualifications/eligible feeder qualifications after 30th April 2025 shall be summarily rejected.
5 Registration with NMC/State Medical Council is mandatory and its documentary proof should be furnished at the test Centre on the examination day.
6 Foreign Nationals including Overseas Citizen of India (OCI) cardholders can appear in NEET-SS 2024 without registration with the National Medical Commission (NMC). The NMC may, on payment of the prescribed fee for registration, grant temporary registration for the duration of the post-doctoral course limited to the medical college/institution to which he/she is admitted for the time being exclusively for pursuing postdoctoral studies. Provided further that temporary registration to such foreign national shall be subject to the condition that such person is duly registered with appropriate registering authority in his/her own country where he has obtained his PG Medical qualification and is duly recognised by the corresponding Medical Council or concerned authority.
7 Candidates already pursuing or have joined a Doctoral Course (DM/MCh/DrNB) through NEET-SS are not eligible for admission to DrNB Superspecialty courses through NEET-SS 2024 for the entire duration prescribed for the course already joined by them earlier. This shall be irrespective of their resignation or discontinuation from the said course due to any reason.
8 The FCPS qualifications awarded by the College of Physicians and Surgeons, Mumbai are not equivalent to either MD or MS courses. Accordingly, candidates possessing FCPS qualifications awarded by the College of Physicians and Surgeons, Mumbai are not eligible to apply for NEET-SS, solely based on their FCPS qualifications.
9 Eligibility of candidates issued admit card for the examination shall be purely provisional. Appearing in NEET-SS 2024 does not confer any automatic rights upon the candidate for admission to DM/MCh/DrNB Super Specialty courses.
Examination Fee
|
Examination Fee per Group* |
Rs. 3500 |
*Excluding charges as may be applicable by various payment gateways. GST has been EXEMPTED as per Department of Revenue, Ministry of Finance, Govt of India circular no 151/07/2021-GST dated 17.06.2021
Candidate shall be required to pay the examination fee as mentioned above for each group in which he/she chooses to appear. For eg. A candidate with MD Paediatrics qualification who chooses to appear in question papers for both Medical and Paediatric Groups shall be required to pay Rs. 3500 + 3500 = 7000/- towards examination fee. Please refer chapter on details of scheme of examination
Applications forms once submitted cannot be withdrawn. Fee shall neither be carried forward to a future date nor refunded under any circumstances. Application once submitted cannot be withdrawn. Any claim for refund, adjustment or carrying forward of Application fee will not be entertained.
How to pay: The prescribed exam fee should be remitted through payment gateway provided using a Credit Card or a Debit Card issued by banks in India or other modes as may be made available and have been provided on the web page. Fee can not be deposited through any mode other than the payment gateway available while submitting online application form submission.
Examination fees in respect of candidates who are absent or have been declared ineligible due to any reason will be forfeited. Candidates are advised to read the information bulletin for NEET SS 2024 carefully and pay examination fee only if they fulfil eligibility criteria prescribed in the bulletin.
Meanwhile, NBEMS will be conducting the NEET-SS 2024 in two slots in 2 days on a computer-based platform at various exam centres across the country. Interested candidates can start submitting the application form for the NEET-SS 2024. Below is the complete schedule-
SCHEDULE
|
S.NO |
PROCESSES |
TIMELINES |
|
1 |
Online Application Submission. |
4th February 2025 (3 PM Onwards) to 24th February 2025 (Till 11:55 PM). |
|
2 |
Edit Window for All Applicants. |
27th February 2025 to 3rd March 2025. |
|
3 |
Final Edit Window to Rectify Deficient/Incorrect Images (No further opportunity shall be given) 1 Photograph. 2 Signatures. 3 Thumb Impression. |
11th March 2025 to 13th March 2025. |
|
4 |
Issue of Admit Card. |
25th March 2025. |
|
5 |
Examination Date. |
29th & 30th March 2025. |
|
6 |
Cut Off Date for qualifying MD/ MS/DNB Broad Specialty qualification towards determination of eligibility for appearing in NEET-SS 2024. |
30th April 2025. |
|
7 |
Declaration of Result. |
By 30th April 2025. |
Powered by WPeMatico
Chandigarh: Amid the ongoing delay in implementing central recruitment and promotion rules, the Faculty Association of Government Medical College and Hospital GMCH, Sector 32, recently held a general body meeting.
Despite Union Home Minister Amit Shah’s announcement in March 2022 that the Central Civil Service Rules would be applied to all employees under the Chandigarh Administration, including GMCH faculty, nearly three years have passed with no action taken to enforce these new rules.
During the recent meeting, this issue was brought to the forefront, where Faculty members of the Government Medical College and Hospital (GMCH), Sector 32, expressed their growing discontent. The recruitment and promotional rules for the teaching faculty were officially notified in the Gazette and were meant to take effect from April 1, 2022. However, faculty members are still waiting for these crucial changes, which has led to significant professional stagnation.
Also Read: Expedite Faculty recruitment in GMCHs, HC tells Maharashtra Govt
In response to this ongoing issue, the Faculty Welfare Body has resolved to give the Chandigarh Administration until March 10, 2025, to take concrete action towards implementing the new rules. If no progress is made by this deadline, the body has warned that they will consider further measures to push for the implementation of the new rules. Prof. Dalal added that they remain committed to advocating for the rights and career progression of their members and will take all necessary steps to resolve the issue.
Although several central rules have already been implemented—such as the retirement age increase from 62 to 65, adjustments to the pay structure, and a reduction in casual leave—the much-anticipated changes to recruitment and promotions have not materialized. This has not only led to professional stagnation but has also delayed new recruitments, resulting in multiple litigations across various departments.
Powered by WPeMatico
New Delhi: The Indian Council of Medical Research (ICMR) has published an addendum to the ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017) to provide a structured ethical framework for Research in Integrative Medicine (RIM).
This initiative marks a significant milestone in strengthening the scientific foundation of Ayush-based integrative healthcare by ensuring ethical rigour and regulatory compliance in research that explores the integration of traditional and modern medical practices.
Secretary, Ministry of Ayush, Vaidya Rajesh Kotecha, highlighted the significance of the development and said, “The addition of these ethical guidelines marks a significant step in encouraging the scientific community to explore Integrative Medicine with greater credibility and confidence.
Also Read:ICMR-NIOH to Host Indo-US Conference on Impact of Climate Change on Health
By providing a structured ethical framework, we aim to inspire researchers to advance evidence-based integration of traditional and modern medicine, ensuring safe, effective, and scientifically validated healthcare solutions for all”.
Integrative Medicine (IM) involves a multimodal approach, where Ayush systems are integrated alongside modern/conventional medicine to enhance patient care and improve health outcomes. With growing global interest in holistic and personalised medicine, it is observed that ethical and regulatory clarity is essential to ensure the credibility, safety, and efficacy of integrative approaches.
This addendum aims to guide researchers, institutions, Ethics Committees (ECs), and regulatory bodies involved in Integrative Medicine research, ensuring that scientific integrity and patient safety remain paramount.
The addendum introduces key measures to enhance the ethical and regulatory framework for Integrative Medicine research. Ethics Committees overseeing such research must now include two Ayush subject-matter experts, with at least one being external to the institution, ensuring well-rounded and informed deliberations. Informed consent standards have been strengthened, requiring that research participants receive clear, tailored information about Integrative Medicine interventions while adhering to India’s standard ethical guidelines for biomedical and clinical research.
Additionally, Ayush-approved medicines used in integrative research will not require extra safety trials or preclinical studies. However, non-codified traditional medicines must undergo the entire regulatory approval process. To ensure compliance, all research must align with the Drugs & Cosmetics Act (1940), New Drugs & Clinical Trial Rules (2019), and Good Clinical Practice (GCP) guidelines specific to Ayush systems.
Powered by WPeMatico
Jaipur: The appointment
of Dr. Pramod Yeole as the new Vice-Chancellor of Rajasthan University of Health Sciences (RUHS) by Governor and Chancellor Haribhau Bagde has triggered
strong opposition from the state’s medical community. The decision has been met
with widespread criticism, as many doctors have expressed concerns about selecting a candidate with a doctoral degree in pharmaceuticals instead of a medical background.
The Rajasthan medical fraternity has strongly opposed the appointment, arguing that a
university primarily focused on medical education should be led by someone with
expertise in clinical medicine. Many doctors have voiced concerns that such a
decision could undermine the credibility of the institution and impact medical
education standards, reports the Times of India. In response to the controversial appointment, medical professionals have threatened to launch a statewide protest if the decision is not reconsidered.
Dr. Yeole’s tenure will
commence once he formally takes charge and will continue for a period of five
years or until he reaches the age of 70, whichever occurs first. Before this
appointment, he served as the Vice-Chancellor of Dr. Babasaheb Ambedkar
Marathwada University (BAMU) in Aurangabad since 2019. Before that, he was Pro-Vice Chancellor at Rashtrasant Tukadoji Maharaj Nagpur University (RTMNU), reports the Daily.
His selection was based
on the recommendations of a designated selection committee and was finalized in
consultation with the state government. Dr. Yeole, who has a PhD in
pharmaceutical sciences, has had an extensive academic career. Before becoming Pro-VC
at RTMNU in June 2015, he spent 15 years as a professor and principal at the Institute
of Pharmaceutical Education and Research, Wardha.
The appointment of a
non-medical person as the new Vice-Chancellor of a health university has
disappointed the medical community. The state branch of the Indian Medical
Association (IMA) has addressed a letter to Governor Haribhau Bagde, asserting
that the appointment of Pramod Yeole as the head of the Rajasthan University of
Health Sciences (RUHS) contradicts the institution’s duty to uphold excellence
in medical education and enhance public healthcare services. The university
oversees 30 affiliated medical colleges.
Another doctor took to social media and stated, “Would a law university appoint an engineer as its Vice Chancellor? Would an IIT accept a humanities graduate for the role? Can a CA become the head of ISRO? Then why is medical education being treated differently?
But the governor has appointed Pramod Yeole, a PhD in pharmaceutical sciences with no MBBS degree, as the Vice Chancellor of Rajasthan University of Health Sciences which is overseeing 30 medical colleges in Rajasthan.
Why is the government making a mockery of medical education? Is the government deliberately trying to collapse the medical education system? Why does the government seem so eager to ruin the future of doctors? How much more damage will the government do to medical education?
Powered by WPeMatico
New Delhi- The National Testing Agency (NTA) is going to close the National Eligibility and Entrance Test-Undergraduate (NEET UG) exam registration window for the academic year 2025 tomorrow, i.e. March 7, 2025, at 11:50 pm. Therefore, candidates are advised to complete the process as early as possible to avoid any last-minute rush.
Meanwhile, the NEET UG exam 2025 application correction window will open on March 9, 2025, and will close on March 11. Following this, the city intimation slip will be released by April 26, 2025, and the admit card will be released by May 1.
STEPS TO REGISTER FOR NEET UG 2025
STEP 1- Visit the official website of NTA.
STEP 2- On the homepage, click on the link that reads, ‘NEET (UG)-2025 registration and online application form’.
STEP 3- A new page will appear on the screen.
STEP 4- Register yourself and proceed to fill in the application form.
STEP 5- Pay the application fee and click on submit.
STEP 6- Take a printout of your application for future reference.
APPLICATION FEE
1 General Candidates: Rs 1,700.
2 General-EWS, OBC-NCL Candidates: Rs 1,600.
3 SC, ST, PwBD, and Third Gender Candidates (for exams within India): Rs 1,000.
4 Candidates Outside India: Rs 9,500.
DOCUMENTS
Candidates should keep the following documents ready before starting the NEET UG 2025 registration and application process-
1 Identification Numbers.
2 APAAR ID Number (if applicable).
3 Past academic records.
4 Documents and images to be uploaded.
5 Alternate or emergency contact details.
6 Parents’ or guardians’ educational qualification and professional information.
7 Annual family income.
8 Credit/Debit Card or Net Banking details.
Powered by WPeMatico
High-dose multivitamins alone or in conjunction with EDTA-based chelation fail to reduce CV events among diabetes patients after MI, suggests a study published in the JAMA.
In 2013, the Trial to Assess Chelation Therapy (TACT) reported that in 1708 patients with stable coronary disease and prior myocardial infarction (MI), oral multivitamins and multiminerals (OMVMs), in a factorial design with edetate disodium (EDTA) chelation therapy, did not reduce cardiovascular events relative to placebo OMVMs, but active EDTA combined with active OMVMs was superior to placebo OMVM/placebo EDTA.
A study was done to compare OMVM vs placebo in terms of efficacy for reducing major adverse cardiovascular events in patients with diabetes and prior MI. The TACT2 randomized, multicenter double-masked 2 × 2 factorial clinical trial took place across 88 sites in the US and Canada.
Participants were 50 years or older, had diabetes, and had an MI 6 weeks ago or more. TACT2 participants were enrolled between September 2016 and December 2020. Data were collected between October 2016 and June 2023. The primary end point was the composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. Results A total of 1000 participants were randomized (500 in the active OMVM group and 500 in the placebo group). The median (IQR) age was 67 (60-72) years, and 730 (73%) were male. Median (IQR) follow-up was 48 (34-58) months.
The primary end point occurred in 175 participants (35%) in the active OMVM group and 175 (35%) in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.80-1.22]; P = .92). The 5-year event rate for the primary end point in the EDTA chelation + active OMVM group was 34.0%; in the EDTA chelation + placebo OMVM group, 35.7%; in the placebo infusion + active OMVM group, 36.0%; and in the placebo infusion + placebo OMVM group, 34.3%.
The comparison of the active infusion + active OMVM with the placebo infusion + placebo OMVM was not significant (HR, 0.91 [95% CI, 0.67-1.23]; P = .54). Although nonsignificant, there was a numerically higher event rate of MI, stroke, mortality from cardiovascular causes in the active OMVM compared to placebo OMVM group. The results of this randomized clinical trial demonstrated that, for participants with chronic coronary disease, diabetes, and a previous MI, high-dose OMVM alone or in conjunction with EDTA-based chelation did not reduce cardiovascular events.
Reference:
Ujueta F, Lamas GA, Anstrom KJ, et al. Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial. JAMA Intern Med. Published online March 03, 2025. doi:10.1001/jamainternmed.2024.8408
Powered by WPeMatico
